Kimelman & Baird’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $48.4M | Buy |
40,384
+60
| +0.1% | +$61.3K | 3.57% | 8 |
|
|
2026
Q1 | $37.1M | Sell |
40,324
-1,554
| -4% | -$1.58M | 3.05% | 12 |
|
|
2025
Q4 | $45M | Sell |
41,878
-1,841
| -4% | -$1.76M | 3.46% | 11 |
|
|
2025
Q3 | $33.4M | Sell |
43,719
-564
| -1% | -$420K | 2.61% | 15 |
|
|
2025
Q2 | $34.5M | Sell |
44,283
-440
| -1% | -$342K | 2.81% | 15 |
|
|
2025
Q1 | $36.9M | Buy |
44,723
+161
| +0.4% | +$134K | 3.14% | 14 |
|
|
2024
Q4 | $34.4M | Buy |
44,562
+7,972
| +22% | +$6.6M | 2.73% | 15 |
|
|
2024
Q3 | $32.4M | Sell |
36,590
-1,370
| -4% | -$1.23M | 2.59% | 15 |
|
|
2024
Q2 | $34.4M | Buy |
+37,960
| New | +$30.4M | 2.83% | 14 |
|
|
2021
Q2 | $14.7M | Buy |
+64,000
| New | +$12.9M | 1.31% | 29 |
|
|
2019
Q3 | $7.16M | Hold |
64,000
| – | – | 0.99% | 35 |
|
|
2019
Q2 | $7.09M | Hold |
64,000
| – | – | 0.99% | 34 |
|
|
2019
Q1 | $8.3M | Hold |
64,000
| – | – | 1.19% | 33 |
|
|
2018
Q4 | $7.41M | Hold |
64,000
| – | – | 1.15% | 33 |
|
|
2018
Q3 | $6.87M | Hold |
64,000
| – | – | 0.87% | 40 |
|
|
2018
Q2 | $5.46M | Buy |
+64,000
| New | +$5.26M | 0.72% | 40 |
|
|
2017
Q4 | $5.42M | Buy |
64,110
+110
| +0.2% | +$9.36K | 0.77% | 42 |
|
|
2017
Q3 | $5.47M | Sell |
64,000
-68,007
| -52% | -$5.58M | 0.82% | 38 |
|
|
2017
Q2 | $10.9M | Sell |
132,007
-27,576
| -17% | -$2.25M | 1.65% | 25 |
|
|
2017
Q1 | $13.4M | Sell |
159,583
-1,380
| -0.9% | -$111K | 2.04% | 16 |
|
|
2016
Q4 | $11.8M | Buy |
160,963
+255
| +0.2% | +$19K | 1.99% | 17 |
|
|
2016
Q3 | $12.9M | Sell |
160,708
-32
| -0% | -$2.56K | 2.27% | 14 |
|
|
2016
Q2 | $12.7M | Buy |
160,740
+288
| +0.2% | +$21.7K | 2.31% | 11 |
|
|
2016
Q1 | $11.6M | Buy |
160,452
+1,655
| +1% | +$125K | 2.16% | 14 |
|
|
2015
Q4 | $13.4M | Buy |
+158,797
| New | +$13.2M | 2.52% | 11 |
|
|
2015
Q2 | $13.6M | Buy |
163,462
+1,035
| +0.6% | +$78.9K | 2.33% | 12 |
|
|
2015
Q1 | $11.8M | Buy |
162,427
+7
| +0% | +$498 | 2.15% | 13 |
|
|
2014
Q4 | $11.2M | Buy |
162,420
+900
| +0.6% | +$60.7K | 2.02% | 15 |
|
|
2014
Q3 | $10.5M | Buy |
161,520
+100
| +0.1% | +$6.33K | 1.98% | 16 |
|
|
2014
Q2 | $10M | Buy |
+161,420
| New | +$9.63M | 1.77% | 21 |
|
Other funds holding LLY
Kimelman & Baird's LLY Position: Q2 2026 in Review
Kimelman & Baird increased its Eli Lilly (LLY) stake by 0.15% in Q2 2026, buying an estimated $61.3K and bringing the position to 40,384 shares worth $48.4M. The position accounts for 3.57% of the portfolio, ranked #8.
Kimelman & Baird first reported a position in LLY in Q2 2014 and has held it in 30 quarters since. 4,599 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Kimelman & Baird held 40,384 shares of Eli Lilly worth $48.4M as of Q2 2026.
- Kimelman & Baird bought 60 Eli Lilly shares in Q2 2026, an estimated $61.3K.
- Eli Lilly made up 3.57% of Kimelman & Baird's portfolio in Q2 2026, its #8 holding.
- Kimelman & Baird first reported a position in Eli Lilly in Q2 2014 and has held it in 30 quarters since.
- 4,599 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Kimelman & Baird's 13F filing for Q2 2026, filed 5 Aug 2026.